Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results:
2012 Fourth-Quarter Sales of $17.6 Billion increased 8.0%; EPS was $0.91
2012 Full-Year Sales of $67.2 Billion increased 3.4%; Full-Year EPS was $3.86
Excluding Special Items, 2012 Fourth-Quarter EPS was $1.19, an increase of 5.3%*
And 2012 Full-Year EPS was $5.10, an increase of 2.0%*
New Brunswick, NJ (January 22, 2013) - Johnson & Johnson today announced sales of $17.6 billion for the fourth quarter of 2012, an increase of 8.0% as compared to the fourth quarter of 2011. Operational results increased 9.3% and the negative impact of currency was 1.3%. Domestic sales increased 6.8%, while international sales increased 8.9%, reflecting operational growth of 11.2% and a negative currency impact of 2.3%. Sales for the fourth quarter of 2012 included the impact of the recently completed acquisition of Synthes, Inc., which contributed 5.6% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business. Worldwide sales for the full-year 2012 were $67.2 billion, an increase of 3.4% versus 2011. Operational sales increased 6.1% and the negative impact of currency was 2.7%. Domestic sales increased 3.2%, while international sales increased 3.5%, reflecting operational growth of 8.4% and a negative currency impact of 4.9%. Sales for the full-year 2012 included the impact of the recently completed acquisition of Synthes, Inc., which contributed 3.1% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.
Net earnings and diluted earnings per share for the fourth quarter of 2012 were $2.6 billion and $0.91, respectively.** Fourth-quarter 2012 net earnings included after-tax special items of $0.8 billion, primarily related to an increase in the litigation accrual and program costs associated with the DePuy ASRTM Hip, in-process research and development, and integration and transaction costs related to the acquisition of Synthes, Inc.
The following information was filed by Johnson Johnson (JNJ) on Tuesday, January 22, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Johnson Johnson's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed, and by Johnson Johnson.
Ticker: JNJ CIK: 200406 Form Type:10-K Annual Report Accession Number: 0000200406-13-000038 Submitted to the SEC: Thu Feb 21 2013 6:44:12 PM EST Accepted by the SEC: Fri Feb 22 2013 Period: Sunday, December 30, 2012 Industry: Pharmaceutical Preparations